Literature DB >> 14962097

Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients.

Giovanni Di Zenzo1, Fabiana Grosso, Michela Terracina, Feliciana Mariotti, Ornella De Pità, Katsushi Owaribe, Alessandro Mastrogiacomo, Francesco Sera, Luca Borradori, Giovanna Zambruno.   

Abstract

Bullous pemphigoid is a subepidermal bullous disease of skin and mucosae associated with autoantibodies to BP180. To characterize the humoral response to BP180, we generated a random BP180 epitope library displayed on lambda bacteriophage. After validation of the library by epitope mapping of three BP180-specific monoclonal antibodies, 15 novel or known BP180 epitopes were identified using 10 bullous pemphigoid serum samples. Fifty-seven bullous pemphigoid and 81 control sera were then assayed against the selected epitopes. Thirty-one out of 57 (54%) bullous pemphigoid sera reacted with at least an additional antigenic site other than the NC16A, within the extracellular (37%) and intracellular (28%) domains of BP180. In addition, the reactivity with extracellular epitopes of BP180 contained within the residue stretches 508-541 and 1331-1404 appeared to be related to the presence of both skin and mucosal involvement. Finally, a preliminary analysis of the epitope pattern in the disease course indicated that bullous pemphigoid patients exhibit a specific reactivity pattern, and that binding to intracellular epitopes of BP180, in addition to NC16A, may be detectable at an early clinical stage. Our findings provide novel insights into the pathophysiology of bullous pemphigoid and show the potential of the utilized approach as a tool for a rapid diagnosis of bullous pemphigoid patients and their management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962097     DOI: 10.1046/j.0022-202X.2003.22126.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  19 in total

Review 1.  Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.

Authors:  William F Pendergraft; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Mol Med (Berl)       Date:  2004-12-11       Impact factor: 4.599

2.  Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.

Authors:  Anna M G Pasmooij; Hendri H Pas; Franciska C L Deviaene; Miranda Nijenhuis; Marcel F Jonkman
Journal:  Am J Hum Genet       Date:  2005-09-09       Impact factor: 11.025

3.  Eosinophil infiltration in three patients with generalized atrophic benign epidermolysis bullosa from a Japanese family: molecular genetic and immunohistochemical studies.

Authors:  Masayo Nomura; Yoh-Ichiro Hamasaki; Ichiro Katayama; Kuniko Abe; Norio Niikawa; Koh-Ichiro Yoshiura
Journal:  J Hum Genet       Date:  2005-09-20       Impact factor: 3.172

4.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

Review 5.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

6.  Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay.

Authors:  Janet A Fairley; Matthew Bream; Colleen Fullenkamp; Sergei Syrbu; Mei Chen; Kelly N Messingham
Journal:  J Am Acad Dermatol       Date:  2012-10-18       Impact factor: 11.527

7.  Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody.

Authors:  Ariane Clapé; Céline Muller; Grégory Gatouillat; Sébastien Le Jan; Coralie Barbe; Bach-Nga Pham; Frank Antonicelli; Philippe Bernard
Journal:  Front Immunol       Date:  2018-03-13       Impact factor: 7.561

8.  Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.

Authors:  Olivier Gaudin; Vannina Seta; Marina Alexandre; Gérôme Bohelay; Françoise Aucouturier; Sabine Mignot-Grootenboer; Saskia Ingen-Housz-Oro; Céline Bernardeschi; Pierre Schneider; Benoît Mellottee; Frédéric Caux; Catherine Prost-Squarcioni
Journal:  Front Immunol       Date:  2018-05-24       Impact factor: 7.561

Review 9.  A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy.

Authors:  Payal M Patel; Virginia A Jones; Christy T Behnam; Giovanni Di Zenzo; Kyle T Amber
Journal:  Antibodies (Basel)       Date:  2021-05-17

Review 10.  Humoral Epitope Spreading in Autoimmune Bullous Diseases.

Authors:  Dario Didona; Giovanni Di Zenzo
Journal:  Front Immunol       Date:  2018-04-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.